Related Experiment Video
Updated: Dec 28, 2025
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Accelerated magnetic seizure therapy (aMST) for treatment of major depressive disorder: A pilot study
Jian Wang1, Fidel Vila-Rodriguez2, Ruiyang Ge2
1Department of Psychiatry, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Background:
Magnetic Seizure therapy (MST) is an emerging treatment for major depressive disorder (MDD) that is associated with fewer cognitive side effects compared to electroconvulsive therapy. The present pilot study sought to investigate whether daily MST treatments were associated to antidepressant effect and assess cognitive side effects associated with an accelerated MST (aMST) treatment schedule.
Methods:
Fifteen MDD patients underwent a six-day course of MST treatment to the vertex following assessment of symptom severity and neuropsychological testing. The primary outcome was severity on the Hamilton Rating Scale for Depression 17-item (HRSD-17). Patient also underwent neuropsychological assessment with the RBANS and Stroop Colour-Word test.
Results:
There were no instances of delirium or disturbance of consciousness following aMST sessions. Patients showed significant decreases on indices of depression and anxiety symptoms, with 9 (60%) patients showing a clinical response and 7 (47%) patients experiencing remission. Significant improvements were reported in RBANS total score, as well as indices of immediate memory and delayed memory. No changes at follow-up were reported for visuospatial/constructional, language, and attention RBANS indices, nor for Stroop Colour/Word performance.
Limitations:
The results should be interpreted with caution as they are part of a non-randomized, open-label pilot study. Further, the short duration of the study does not provide longitudinal follow-up to determine whether treatment response lasts a meaningful duration of time.
Conclusions:
aMST well tolerated without significant evidence of cognitive side effects and rapid improvement in symptoms. Further research is required to fully characterize these changes and replicate them in independent samples.
Insights
Accelerated Magnetic Seizure Therapy (aMST) shows promise for treating major depressive disorder (MDD), offering rapid symptom improvement with minimal cognitive side effects. This pilot study indicates aMST is well-tolerated and effective for depression and anxiety.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Psychology
Background:
- Magnetic Seizure Therapy (MST) is an emerging neuromodulation technique for treating major depressive disorder (MDD).
- MST is associated with fewer cognitive side effects compared to electroconvulsive therapy (ECT).
- Accelerated MST (aMST) involves a more frequent treatment schedule.
Purpose of the Study:
- To investigate the antidepressant effects of a daily aMST treatment schedule.
- To assess the cognitive side effects associated with an accelerated MST protocol.
- To evaluate the tolerability and safety of aMST in MDD patients.
Main Methods:
- A pilot study involving 15 MDD patients undergoing a six-day aMST treatment course.
- Symptom severity assessed using the Hamilton Rating Scale for Depression (HRSD-17).
- Neuropsychological testing included the RBANS and Stroop Colour-Word test.
Main Results:
- No instances of delirium or disturbance of consciousness were reported.
- Significant reductions in depression and anxiety symptoms were observed.
- 60% of patients showed a clinical response, and 47% achieved remission.
- Improvements in immediate and delayed memory were noted (RBANS scores).
- No significant changes in visuospatial/constructional skills, language, attention, or Stroop performance were found.
Conclusions:
- aMST was well-tolerated with no significant cognitive side effects.
- Rapid symptom improvement was observed in MDD patients.
- Further research is needed to confirm these findings and assess long-term efficacy.
